Race against time: major trial tests new hope to slow devastating ALS
NCT ID NCT07322003
Summary
This study aims to find out if a drug called pridopidine can slow the progression of ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease). It will involve about 500 adults with early and rapidly progressing ALS. For the first 48 weeks, some participants will take pridopidine and others will take a placebo (a pill with no medicine), and then all participants will have the option to take pridopidine for another 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sean M. Healey & AMG Center for ALS
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Somnos Clinical Research
RECRUITINGLincoln, Nebraska, 68506, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Texas Neurology
RECRUITINGDallas, Texas, 75206, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.